Manage Tickers Link Financial Account

Has my stock been accused of fraud?Join over 160k users who know.

Ticker	Price	Change($)	Change(%)	Shares	Volume	Prev Close	Open	Gain($)	Gain(%)

Ticker	Status	Jurisdiction	Filing Date	CP Start	CP End	CP Loss	Deadline

Ticker	Case Name	Status	CP Start	CP End	Deadline	Settlement Amt

Ticker	Name	Date	Analyst Firm	Up/Down	Target ($)	Rating Change	Rating Current

Piper Sandler Reiterates Neutral on Biogen, Raises Price Target to $157

Author: Benzinga Newsdesk | November 21, 2025 12:15pm

Piper Sandler analyst David Amsellem reiterates Biogen (NASDAQ:BIIB) with a Neutral and raises the price target from $118 to $157.

Posted In: BIIB